Immunotherapie bij endometriumcarcinoom: overzicht van recente vooruitgang

Immunotherapy with immune checkpoint inhibitors (ICI) has become a transformative pillar in cancer treatment, offering significant improvements in survival and reducing treatment-related side effects compared to traditional therapies. In gynecologic cancers, ICIs have transformed the treatment of endometrial (EC) and cervical cancers, whereas they have not demonstrated clinical benefit in ovarian cancer. This review examines the current state of ICI advancements in EC. Given the unique immunological characteristics of EC, a comprehensive understanding of advancements is crucial for optimizing decision-making and patient outcomes. While ICIs have demonstrated robust and durable efficacy in dMMR/MSI-H EC, the magnitude of benefit in pMMR disease remains modest. Additionally, we examine promising future directions, including personalized immunotherapy approaches and novel combination therapies (e.g. antibody-drug conjugates, PARP inhibitors, antiangiogenic drugs).